We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Mar 21
Novartis will manufacture the mRNA and bulk drug product for up to 50 million doses of the CVnCoV…
04 Mar 21
Exscientia intends to use proceeds from the financing round to further advance AI drug discovery platform and portfolio
04 Mar 21
The expanded approval is based on CROWN trial, which showed that treatment using Lorbrena reduced the risk of…
01 Mar 21
The Covid-19 vaccine has been granted emergency use authorisation after evaluation of safety, effectiveness and manufacturing quality by…
26 Feb 21
Takeda will continue to manufacture and supply the products under the sale to Teijin Pharma
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Feb 21
The Phase 1/2/3 trial evaluates the safety and tolerability of a third dose of BNT162b2 and its effectiveness…
25 Feb 21
AbbVie claims that HUMIRA is the first and only subcutaneous biologic treatment for active ulcerative colitis in paediatric…
25 Feb 21
PRA shareholders will own around 34% of the shares of the combined company and ICON shareholders will own…
23 Feb 21
The Phase 2 trial is designed to determine the appropriate antigen dosage for Phase 3 evaluation of their…
19 Feb 21
The Phase 2/3 study will enrol healthy pregnant women, aged 18 years and older, and vaccinate them during…